Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00155 |
DKK1 C terminal Domain Protein, Human, Recombinant (hFc & Avi)
hDkk-1,Dickkopf-1,Dk... |
Human | HEK293 Cells |
Dickkopf-1 (Dkk1), the founding and best-studied member of the Dkk family, functions as an antagonist of canonical Wnt/β-catenin. Dkk1 is considered to play a broad role in a variety of biological processes. DKK1 C terminal Domain Protein, Human, Recombinant (hFc & Avi) is expressed in HEK293 mammalian cells with C-hFc-Avi tag. The predicted molecular weight is 38.69 kDa and the accession number is O94907. | |||
TMPK-00157 |
DKK1 C terminal Domain Protein, Human, Recombinant (hFc & Avi), Biotinylated
hDkk-1,SK,Dkk1,Dic |
Human | HEK293 Cells |
Dickkopf-1 (Dkk1), the founding and best-studied member of the Dkk family, functions as an antagonist of canonical Wnt/β-catenin. Dkk1 is considered to play a broad role in a variety of biological processes. DKK1 C terminal Domain Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-hFc-Avi tag. The predicted molecular weight is 38.69 kDa and the accession number is O94907. | |||
TMPK-00156 |
DKK1 N terminal Domain Protein, Human, Recombinant (hFc & Avi)
Dickkopf-1,Dkk1,hDkk... |
Human | HEK293 Cells |
Dickkopf-1 (Dkk1), the founding and best-studied member of the Dkk family, functions as an antagonist of canonical Wnt/β-catenin. Dkk1 is considered to play a broad role in a variety of biological processes. DKK1 N terminal Domain Protein, Human, Recombinant (hFc & Avi) is expressed in HEK293 mammalian cells with C-hFc-Avi tag. The predicted molecular weight is 40.25 kDa and the accession number is O94907. | |||
TMPK-00158 |
DKK1 N terminal Domain Protein, Human, Recombinant (hFc & Avi), Biotinylated
hDkk1,Dkk1,Dick... |
Human | HEK293 Cells |
Dickkopf-1 (Dkk1), the founding and best-studied member of the Dkk family, functions as an antagonist of canonical Wnt/β-catenin. Dkk1 is considered to play a broad role in a variety of biological processes. DKK1 N terminal Domain Protein, Human, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-hFc-Avi tag. The predicted molecular weight is 40.25 kDa and the accession number is O94907. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01534 |
Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human&Mouse, MHC (His & Avi)
RING12,PSMB9,Proteasome chain 7,RMF,LMP-2,... |
Human & Mouse | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01523 |
Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Monomer Protein, Human&Mouse, MHC (His & Avi)
WAGR,WT33,AWT1,GUD,RMF,WT1,WIT-2,MHC |
Human & Mouse | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01535 |
Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Tetramer Protein, Human&Mouse, MHC (His & Avi)
Macropain chain 7,LMP2,Proteasome c |
Human & Mouse | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01522 |
Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Tetramer Protein, Human&Mouse, MHC (His & Avi)
RMF,WT33,WIT-2,MHC,WAGR,AWT1,GUD,WT1 |
Human & Mouse | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. |